The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis
Open accessAbstract
PURPOSE: Radiofrequency ablation (RFA) and microwave ablation (MWA) are the two main percutaneous techniques for the treatment of unresectable hepatocellular carcinoma (HCC). However, to date, studies comparing the two therapies have provided discordant results. The aim of this meta-analysis is to evaluate the efficacy and safety of the two treatments for HCC patients. MATERIALS AND METHODS: A computerised bibliographic search was performed on PubMed/MEDLINE, Embase, Google Scholar and Cochrane library databases. The rates of complete response (CR), local recurrence (LRR), 3-year survival (SR) and major complications were compared between the two treatment groups by using the Mantel-Haenszel test in cases of low heterogeneity or the DerSimonian and Laird test in cases of high heterogeneity. Sources of heterogeneity were investigated using subgroup analyses. In order to confirm our finding, sensitivity analysis was performed restricting the analysis to high-quality studies. RESULTS: One randomised controlled trial (RCT) and six retrospective studies with 774 patients were included in the meta-analysis. A non-significant trend of higher CR rates in the patients treated with MWA was found (odds ratio (OR) = 1.12, 95% confidence interval (CI) 0.67-1.88, p = 0.67]. Overall LRR was similar between the two treatment groups (OR 1.01, 95% CI 0.53-1.87, p = 0.98) but MWA outperformed RFA in cases of larger nodules (OR 0.46, 95% CI 0.24-0.89, p = 0.02). 3-year SR was higher after RFA without statistically significant difference (OR 0.95, 95% CI 0.58-1.57, p = 0.85). Major complications were more frequent, although not significantly, in MWA patients (OR 1.63, 95% CI 0.88-3.03, p = 0.12). CONCLUSIONS: Our results indicate a similar efficacy between the two percutaneous techniques with an apparent superiority of MWA in larger neoplasms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“Comparisons between the two treatment groups across all the studies included were performed by using the Mantel-Haenszel test for fixed-effects models [11] (in case of low heterogeneity) or the DerSimonian and Laird test for random-effects models [12] (in case of high heterogeneity).”
MethodPreferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
(2014) · Medical Entomology and Zoology · Cited by 17,633
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J. P. T., Green, S. R., & Higgins, J. P. T. (2008) · Cited by 7,171
El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
(2012) · Hepatogastroenterology · doi:10.5754/hge12183 · Cited by 1,625
Shibata, T., Iimuro, Y., Yamamoto, Y., Maetani, Y., Ametani, F., Itoh, K., & Konishi, J. (2002) · Radiology · doi:10.1148/radiol.2232010775 · Cited by 575
Local-Regional Treatment of Hepatocellular Carcinoma
Lencioni, R., & Crocetti, L. (2012) · Radiology · doi:10.1148/radiol.11110144 · Cited by 514
Robins, J., Breslow, N., & Greenland, S. (1986) · Biometrics · doi:10.2307/2531052 · Cited by 476
Yin, X., Xie, X., Lu, M., Xu, H., Xu, Z., Kuang, M., Liu, G., Liang, J., & Lau, W. Y. (2009) · Cancer · doi:10.1002/cncr.24196 · Cited by 158
Izumi, N., Asahina, Y., Noguchi, O., Uchihara, M., Kanazawa, N., Itakura, J., Himeno, Y., Miyake, S., Sakai, T., & Enomoto, N. (2001) · Cancer · doi:10.1002/1097-0142(20010301)91:5<949::aid-cncr1084>3.0.co;2-h · Cited by 126
Radiofrequency ablation for hepatocellular carcinoma
Nishikawa, H., Kimura, T., Kita, R., & Osaki, Y. (2013) · International Journal of Hyperthermia · doi:10.3109/02656736.2013.821528 · Cited by 113
Chinnaratha, M. A., Chuang, M.-Y. A., Fraser, R. J., Woodman, R. J., & Wigg, A. J. (2015) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13028 · Cited by 102
Simo, K. A., Sereika, S. E., Newton, K. N., & Gerber, D. A. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.21933 · Cited by 88
Facciorusso, A., Prete, V. D., Antonino, M., Neve, V., Crucinio, N., Leo, A. D., Carr, B. I., & Barone, M. (2014) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12618 · Cited by 77
Self-citationPost-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation
Facciorusso, A., Prete, V. D., Antonino, M., Crucinio, N., Neve, V., Leo, A. D., Carr, B. I., & Barone, M. (2014) · Digestive and Liver Disease · doi:10.1016/j.dld.2014.07.012 · Cited by 73
Self-citationHocquelet, A., Balageas, P., Laurent, C., Blanc, J., Frulio, N., Salut, C., Cassinotto, C., Saric, J., Possenti, L., Bernard, P., et al. (2015) · International Journal of Hyperthermia · doi:10.3109/02656736.2015.1068382 · Cited by 67
Long-Term Outcome of Percutaneous Ablation in Very Early-Stage Hepatocellular Carcinoma
Kuang, M., Xie, X., Huang, C., et al. (2011) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-011-1716-2 · Cited by 47
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Llovet, J. M., De Baere, T., Kulik, L., Haber, P. K., Greten, T. F., Meyer, T., & Lencioni, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00395-0 · Cited by 1,044
Dimitroulis, D., Damaskos, C., Valsami, S., Davakis, S., Garmpis, N., Spartalis, E., Athanasiou, A., Moris, D., Sakellariou, S., Kykalos, S., et al. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i29.5282 · Cited by 330
NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options
Foerster, F., Gairing, S. J., Müller, L., & Galle, P. R. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.007 · Cited by 280
Metadata
- Authors
- Facciorusso, A., Di Maso, M., & Muscatiello, N.
- Venue
- International Journal of Hyperthermia
- Publisher
- Informa UK Limited
- Published
- 2016-01-21
- Volume
- 32
- Issue
- 3
- Pages
- 339-344
- ISSN
- 0265-6736 (ISSN-L)
- 1464-5157
- OpenAlex
- W2264268116
- Cited by
- 267
- References
- 21
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.